Profile data is unavailable for this security.
About the company
Faron Pharmaceuticals Oy is a Finland-based clinical stage biopharmaceutical company. The company has three drug candidates all based on mastering immune modulation and, as a result, tackling unmet needs in cancer, preventing organ damage and treating blood count abnormalities. The Company's goal is to build future immunotherapy, i.e., to bring new treatments to patients by affecting the immune system. Faron’s drug candidate, Traumakine, is a drug developed by the Company to prevent multi-organ damage and excessive inflammatory responses. Another drug candidate, Haematokine, promotes the expansion of bone marrow stem cells. It is being developed, e.g., for the treatment of chemotherapyinduced neutropenia (CIN). In neutropenia patients have less blood cells called neutrophils than normal due to cancer treatment.
- Revenue in GBP (TTM)0.00
- Net income in GBP-26.18m
- Incorporated2006
- Employees34.00
- LocationFaron Pharmaceuticals OyJoukahaisenkatu 6TURKU 20520FinlandFIN
- Phone+358 24695151
- Fax+358 24695152
- Websitehttps://www.faron.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oxford Biodynamics PLC | 617.00k | -11.11m | 23.89m | 45.00 | -- | 9.55 | -- | 38.72 | -0.0643 | -0.0643 | 0.0035 | 0.008 | 0.0487 | 1.20 | 0.379 | 13,711.11 | -87.64 | -39.72 | -114.28 | -45.52 | 41.49 | -- | -1,800.32 | -1,324.62 | 0.6156 | -87.72 | 0.7873 | -- | 231.17 | -15.53 | -61.34 | -- | -1.60 | -- |
| Incanthera PLC | 0.00 | -1.48m | 33.25m | 8.00 | -- | -- | -- | -- | -0.0192 | -0.0192 | 0.00 | -0.0086 | 0.00 | -- | -- | 0.00 | -373.20 | -101.74 | -- | -132.88 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -36.11 | -- | -- | -- |
| Arecor Therapeutics PLC | 4.57m | -8.55m | 35.99m | 50.00 | -- | 3.78 | -- | 7.87 | -0.2793 | -0.2793 | 0.1493 | 0.3111 | 0.2462 | -- | 1.33 | 91,460.00 | -46.06 | -- | -60.53 | -- | -- | -- | -187.05 | -- | 2.02 | -- | 0.0343 | -- | 90.30 | -- | 7.62 | -- | -- | -- |
| Sareum Holdings Plc | 0.00 | -4.26m | 36.16m | 5.00 | -- | 56.45 | -- | -- | -0.0614 | -0.0614 | 0.00 | 0.0059 | 0.00 | -- | -- | 0.00 | -160.20 | -71.41 | -195.05 | -81.48 | -- | -- | -- | -19,709.24 | -- | -6.61 | 0.00 | -- | -- | -- | -46.96 | -- | -- | -- |
| Poolbeg Pharma PLC | 0.00 | -3.93m | 69.00m | 8.00 | -- | 4.78 | -- | -- | -0.0079 | -0.0079 | 0.00 | 0.0289 | 0.00 | -- | -- | 0.00 | -22.65 | -- | -24.00 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 16.11 | -- | -- | -- |
| Scancell Holdings Plc | 0.00 | -11.32m | 95.28m | 51.00 | -- | -- | -- | -- | -0.0138 | -0.0138 | 0.00 | -0.0102 | 0.00 | -- | -- | 0.00 | -37.31 | -33.32 | -40.52 | -35.82 | -- | -- | -- | -817.98 | -- | -- | 1.73 | -- | -- | -- | -161.24 | -- | 77.85 | -- |
| Faron Pharmaceuticals Oy | 0.00 | -26.18m | 98.19m | 34.00 | -- | -- | -- | -- | -0.2815 | -0.2815 | 0.00 | -0.1308 | 0.00 | -- | -- | 0.00 | -287.97 | -213.06 | -- | -963.12 | -- | -- | -- | -- | -- | -12.02 | -- | -- | -- | -- | -7.71 | -- | -16.05 | -- |
| Futura Medical PLC | 3.10m | -6.51m | 110.71m | 12.00 | -- | 20.18 | -- | 35.70 | -0.0219 | -0.0219 | 0.0105 | 0.0182 | 0.3391 | -- | 5.09 | 258,414.20 | -71.22 | -79.25 | -127.75 | -127.22 | 57.22 | -- | -210.03 | -914.37 | 1.47 | -- | 0.00 | -- | -- | -- | -11.40 | -- | 219.68 | -- |
| hVIVO PLC | 56.04m | 16.12m | 188.46m | 274.00 | 11.84 | 5.49 | 10.01 | 3.36 | 0.0234 | 0.0234 | 0.0817 | 0.0505 | 0.8327 | -- | 4.08 | 204,536.50 | 23.94 | -0.643 | 46.27 | -1.29 | -- | -- | 28.75 | -0.765 | 1.47 | -- | 0.2674 | -- | 15.61 | 35.40 | 2,176.68 | -- | 136.55 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Keskin�inen Ty�el�kevakuutusyhti� Varmaas of 24 Jun 2024 | 4.60m | 6.39% |
| Fj�rde AP-fondenas of 24 Jun 2024 | 3.59m | 4.99% |
| OP Asset Management Ltd.as of 31 Dec 2023 | 2.00m | 2.78% |
| Sp-Fund Management Co. Ltd.as of 31 May 2024 | 800.04k | 1.11% |
| Danske Bank A/S (Investment Management Finland)as of 31 May 2024 | 431.72k | 0.60% |
| Fondita Fund Management Co. Ltd.as of 31 May 2024 | 330.49k | 0.46% |
| Canaccord Genuity Wealth Ltd.as of 30 Sep 2023 | 159.68k | 0.22% |
| Veikko Laine Oyas of 31 May 2024 | 148.00k | 0.21% |
| Aktia Varainhoito Oyas of 31 Oct 2021 | 117.37k | 0.16% |
| Janus Henderson Investors UK Ltd.as of 31 Mar 2024 | 100.00k | 0.14% |
